

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Albert Lai

Serial No.: 10/574,182 Group Art Unit: 1646

Filed: May 31, 2007 Examiner: to be assigned

For: NOVEL SPLICE VARIANTS OF HUMAN DKKL1

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 AND §1.97(b)(3)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The citations listed on the enclosed Information Disclosure Form PTO/SB/08a may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present application.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.


The Commissioner is hereby authorized to charge any fees in connection with this Information Disclosure Statement to Deposit Account No. 50-4409. This, however, is not an authorization for payment of Issue Fee.

Respectfully submitted,

June 14, 2010

Novartis Vaccines and Diagnostics, Inc.
Intellectual Property – X-100B
PO Box 8097
Emeryville, CA 94662-8097
(510) 923-2438
(510) 655-3542 (fax)

By:


David A. Carpenter
Attorney for the Applicants
Reg. No. 45,945